肿瘤细胞治疗研究
英文原题：Spliced to kill: RNA mis-splicing derived cancer neoantigens.
Spliced to kill: RNA mis-splicing derived cancer neoantigens.
在癌症治疗中应用基于新抗原的方法所面临的重大挑战之一，是鉴定癌症特异性新抗原，尤其是患者之间共享的新抗原。
基于新抗原的肿瘤治疗面临的主要挑战之一，是识别肿瘤特异性新抗原，尤其是能够在不同患者间共享的新抗原。Kim 等人在近期报告中发现，剪接因子突变的髓系恶性肿瘤可产生一种新的肿瘤新抗原来源。这些异常剪接产生的新抗原，为工程化 TCR-T 细胞疗法和新抗原疫苗带来了新机会。
One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR-T cell therapies and neoantigen-based vaccines.
MEMBER ACCOUNT
登录成功会直接打开下一页。
